Literature DB >> 464451

Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.

R A O'Reilly, C H Motley.   

Abstract

Eleven normal humans were studied to evaluate the reported interaction of racemic sodium warfarin and trimethoprim-sulfamethoxazole prospectively. Single oral doses of racemic warfarin, 1.5 mg/kg of body weight, were administered with and without 320 mg of trimethoprim and 1600 mg of sulfamethoxazole orally, beginning 7 d before the warfarin and continuing daily throughout the hypoprothrombinemia. Daily plasma samples were analyzed for one-stage prothrombin activity (Quick) and for warfarin content by high-pressure liquid chromatography. Transient cutaneous reactions developed in four of 11 subjects: a morbilliform rash in three (studies discontinued) and generalized pruritus in one. A highly significant augmentation of the warfarin effect on the mean one-stage prothrombin activity (P less than 0.03) occurred with trimethoprim-sulfamethoxazole, but no significant effect was found on the warfarin half-life (P greater than 0.5). It is concluded that trimethoprim-sulfamethoxazole interacts with racemic warfarin, possibly at a receptor-site locus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 464451     DOI: 10.7326/0003-4819-91-1-34

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Lack of effect of co-trimoxazole on the pharmacokinetics and pharmacodynamics of nifedipine.

Authors:  C Edwards; S Monkman; S Cholerton; M D Rawlins; J R Idle; R E Ferner
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Current antibiotic usage II: Aminoglycosides, tetracyclines, erythromycin, vancomycin and sulphonamides.

Authors:  S M Merchant; N P Vithlani
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

Review 5.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

6.  The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.

Authors:  Jeffrey J Glasheen; Randolph V Fugit; Allan V Prochazka
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

Review 7.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

8.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

9.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

Authors:  C Banfield; R O'Reilly; E Chan; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 10.  Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

Authors:  A K Scott
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.